Skip to content
AveXis logo — Specializing in groundbreaking gene therapies for rare neuro...

AveXis

Specializing in groundbreaking gene therapies for rare neurological genetic diseases, impacting lives profoundly.

Founded 2013 Grant Total: $75.10M Biotechnology, Health Care

General Information

Company Name AveXis
Founded Year 2013
Founders / Decision Makers
Team member
Industries Biotechnology, Health Care
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with AveXis. To contact AveXis, visit avexis.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does AveXis compare?

A PDF of AveXis and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting AveXis soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About AveXis

AveXis is a biotechnology startup specializing in groundbreaking gene therapies for rare neurological genetic diseases, impacting lives profoundly. Founded in 2013, the company was later acquired by Novartis on May 14, 2018, and adopted the name Novartis Gene Therapies in 2020. AveXis focuses on developing and bringing to market innovative gene therapies for individuals and families impacted by rare and severe neurological genetic disorders. The company received a $100.00K grant investment on 01 January 2019 from the North Carolina Biotechnology Center. Specializing in the biotechnology and health care industries, AveXis has shown potential for addressing critical medical needs through advanced genetic therapies.

Business keywords: Gene Therapy, Neurological Genetic Diseases, Rare Diseases, Medical Innovation, Novartis, Acquisition, Life-Threatening Conditions, Research & Development, Therapeutic Innovations

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $100.00K 1
North Carolina Biotechnology Center
01 Jan 2019
Series D $65.00M 9
RA Capital Management, Venrock +7
08 Sep 2015
Series C $10.00M -
09 Jan 2015
Series B Undisclosed -
22 Apr 2014
Series A Undisclosed -
27 Jul 2013

AveXis Alternatives & Competitors

View All Alternatives
AveXis vs

Pioneering gene therapies for rare neurological and liver diseases, targeting Alpha-1 Antitrypsin De...

Series A
Biotechnology, Health Care
AveXis vs

Dedicated to addressing the root cause of rare genetic diseases and promising hope for patients in n...

Post-IPO Equity
Biotechnology, Health Care
AveXis vs
VectivBio
VectivBio Switzerland

Biotech company develops treatments for severe rare diseases, aims to become global leader with pati...

Acquired
57 employees
Biotechnology, Health Care

FAQ About AveXis

Specializing in groundbreaking gene therapies for rare neurological genetic diseases, impacting lives profoundly.
AveXis was founded in 2013.
AveXis operates in Biotechnology and Health Care. Its work centres on Gene Therapy, Neurological Genetic Diseases, Rare Diseases and Medical Innovation.
AveXis has completed 5 funding rounds, raising a total of $75.10M. The latest funding stage is Grant.
Top alternatives and competitors to AveXis include Apic Bio, Homology Medicines, VectivBio, Alcyone Lifesciences, Orchard Therapeutics - U.S.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AveXis and Apic Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AveXis, https://bouncewatch.com/company/avexis, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout